Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.798 USD | +5.44% | -8.96% | +71.96% |
Apr. 12 | Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial | MT |
Apr. 11 | Top Premarket Gainers | MT |
Evolution of the average Target Price on Lipocine Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Lipocine Inc.
HC Wainwright | |
Cantor Fitzgerald | |
Ladenburg Thalmann |
EPS Revisions
- Stock Market
- Equities
- LPCN Stock
- Consensus Lipocine Inc.